Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shinya Hiramitsu

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Circulation Journal : Official Journal of the Japanese Circulation Society|April 12, 2026
Prevalence and Clinical Characteristics of Patients With Heart Failure With Preserved Ejection Fraction Who Meet the Obesity-Related Eligibility Criteria for Subcutaneous Incretin Receptor Agonists in Japan　- Insights From the PARACLETE StudyKen Nishikawa, Sho Suzuki, Masatoshi Minamisawa, et al.
Journal of Lipid Research|October 16, 2015
Reduction of serum FABP4 level by sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes mellitusMasato Furuhashi, Shinya Hiramitsu, Tomohiro Mita, et al.
Circulation Reports|March 11, 2021
Rationale and Design of the CANONICAL Study　- Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Canagliflozin for Heart Failure With Preserved Ejection Fraction With Type 2 Diabetes MellitusShu Kasama, Tohru Masuyama, Shiro Uemura, et al.
Advances in Therapy|September 21, 2023
Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetes Mellitus Undergoing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors (EAGLE-DH)Hirohiko Motoki, Yoshito Inobe, Toshiki Fukui, et al.
Heart and Vessels|November 1, 2016
Assessment of trough rivaroxaban concentrations on markers of coagulation activation in nonvalvular atrial fibrillation populationFumihiko Kitagawa, Junnichi Ishii, Shinya Hiramitsu, et al.
Obesity (Silver Spring, Md.)|December 19, 2014
FABP4 is secreted from adipocytes by adenyl cyclase-PKA- and guanylyl cyclase-PKG-dependent lipolytic mechanismsTomohiro Mita, Masato Furuhashi, Shinya Hiramitsu, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|May 25, 2022
New Conversion Formula Between B-Type Natriuretic Peptide and N-Terminal-Pro-B-Type Natriuretic Peptide　- Analysis From a Multicenter StudySatomi Ishihara, Shinya Hiramitsu, Koshiro Kanaoka, et al.
ESC Heart Failure|June 25, 2020
Rationale and design of the EMPYREAN studyHirohiko Motoki, Izuru Masuda, Shinji Yasuno, et al.
Journal of Cardiology|December 2, 2006
[Promising efficacy of the sirolimus-eluting stent in patients with acute myocardial infarction]Tomoko Gochi, Hisashi Umeda, Naoki Yoshida, et al.
Journal of Cardiology|March 24, 2016
Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemiaSunao Kojima, Kunihiko Matsui, Hisao Ogawa, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Circulation Journal : Official Journal of the Japanese Circulation Society|April 12, 2026
Prevalence and Clinical Characteristics of Patients With Heart Failure With Preserved Ejection Fraction Who Meet the Obesity-Related Eligibility Criteria for Subcutaneous Incretin Receptor Agonists in Japan　- Insights From the PARACLETE StudyKen Nishikawa, Sho Suzuki, Masatoshi Minamisawa, et al.
Journal of Lipid Research|October 16, 2015
Reduction of serum FABP4 level by sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes mellitusMasato Furuhashi, Shinya Hiramitsu, Tomohiro Mita, et al.
Circulation Reports|March 11, 2021
Rationale and Design of the CANONICAL Study　- Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Canagliflozin for Heart Failure With Preserved Ejection Fraction With Type 2 Diabetes MellitusShu Kasama, Tohru Masuyama, Shiro Uemura, et al.
Advances in Therapy|September 21, 2023
Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetes Mellitus Undergoing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors (EAGLE-DH)Hirohiko Motoki, Yoshito Inobe, Toshiki Fukui, et al.
Heart and Vessels|November 1, 2016
Assessment of trough rivaroxaban concentrations on markers of coagulation activation in nonvalvular atrial fibrillation populationFumihiko Kitagawa, Junnichi Ishii, Shinya Hiramitsu, et al.
Obesity (Silver Spring, Md.)|December 19, 2014
FABP4 is secreted from adipocytes by adenyl cyclase-PKA- and guanylyl cyclase-PKG-dependent lipolytic mechanismsTomohiro Mita, Masato Furuhashi, Shinya Hiramitsu, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|May 25, 2022
New Conversion Formula Between B-Type Natriuretic Peptide and N-Terminal-Pro-B-Type Natriuretic Peptide　- Analysis From a Multicenter StudySatomi Ishihara, Shinya Hiramitsu, Koshiro Kanaoka, et al.
ESC Heart Failure|June 25, 2020
Rationale and design of the EMPYREAN studyHirohiko Motoki, Izuru Masuda, Shinji Yasuno, et al.
Journal of Cardiology|December 2, 2006
[Promising efficacy of the sirolimus-eluting stent in patients with acute myocardial infarction]Tomoko Gochi, Hisashi Umeda, Naoki Yoshida, et al.
Journal of Cardiology|March 24, 2016
Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemiaSunao Kojima, Kunihiko Matsui, Hisao Ogawa, et al.
Pageof 6